U87-luc Orthotopic Mouse Model Service for Brain Cancer

The U87-luc orthotopic mouse model delivers the most historically established human glioblastoma multiforme platform, characterized by epithelial morphology, CDKN2A deletion, PTEN pathway alteration, and robust luciferase reporter expression, enabling real-time bioluminescence tracking of intracranial tumor growth and therapeutic response in immunodeficient hosts. Alfa Cytology constructs, validates, and manages this classic human xenograft glioma system with integrated imaging and comprehensive neuropathological endpoints, supplying researchers with reproducible preclinical data to advance anti-angiogenic, nanotherapeutic, and combination chemotherapy discovery programs.

Overview of U87-luc Orthotopic Mouse Model for Brain Cancer

The U87-luc orthotopic model is established by stereotactically implanting luciferase-transduced U87 MG human glioblastoma cells into the striatum of immunodeficient nude mice, generating an intracranial tumor that recapitulates the epithelial-like morphology, hypercellularity, and angiogenic drive characteristic of human glioblastoma multiforme. Originally established in 1966 at Uppsala University, Sweden, from a 44-year-old patient with malignant glioma, the U87 MG line is the most extensively utilized glioblastoma cell line in preclinical neuroscience and has served as the foundational substrate for seminal discoveries in glioma biology, anti-angiogenic therapy, and nanomedicine. The stable integration of firefly luciferase permits non-invasive, longitudinal bioluminescence imaging of tumor burden deep within the brain parenchyma, providing a sensitive quantitative readout for monitoring engraftment success, exponential growth, and therapy-induced regression without serial magnetic resonance imaging or repeated terminal sampling.

Fig 1. Dynamic imaging of the U-87 MG in situ model using BLI (Day 7/14/21/28, A: 1×10⁴, B: 1×10⁵, C: 3×10⁵; D: 5 mice side by side). (Kim, Woong, et al., 2015)

Histologically, U87-luc tumors display features consistent with high-grade glioma, including dense cellularity, nuclear atypia, microvascular proliferation, and pseudopalisading necrosis. The cell line harbors homozygous deletion of the CDKN2A locus and inactivating PTEN mutations, alongside robust epidermal growth factor receptor expression and established sensitivity to temozolomide. With a long-standing track record in anti-angiogenic drug evaluation, magnetic hyperthermia studies, and nanoparticle-based delivery investigations, the U87-luc model occupies a singular position as the benchmark human glioblastoma xenograft for evaluating vascular-targeting agents, thermo-ablative therapies, and blood-brain barrier-penetrant nanocarriers in a human-relevant preclinical setting.

Cell Line Information: U87-luc

U87-luc is a luciferase-reporter derivative of the U87 MG human glioblastoma cell line, generated through lentiviral transduction to stably express firefly luciferase for in vivo bioluminescent tracking. The parental U87 MG line was originally established in 1966 at Uppsala University, Sweden, from a malignant glioma of a 44-year-old patient and has since become the most widely employed human glioblastoma model in preclinical neuro-oncology research. Key attributes are summarized below:

Our Services

Alfa Cytology delivers comprehensive U87-luc orthotopic glioblastoma model services encompassing stereotactic surgical implantation in immunodeficient hosts, longitudinal bioluminescence imaging, magnetic resonance imaging integration, and detailed neuropathological endpoint analysis with CD31, Ki67, and human-specific marker immunohistochemistry. Every study is conducted within fully accredited vivarium facilities under IACUC oversight, ensuring scientific precision, ethical compliance, and complete data traceability from model construction through final report delivery.

Workflow of U87-luc Orthotopic Mouse Model Construction

Construction of the U87-luc orthotopic glioblastoma model employs stereotactic intracranial injection to deliver human tumor cells into the striatum of immunodeficient nude mice, ensuring reproducible engraftment, minimal surgical morbidity, and consistent growth kinetics. The protocol integrates pre-operative analgesia, aseptic stereotactic surgery, controlled cell infusion, and longitudinal bioluminescence monitoring, as detailed below:

1. Cell Preparation and Batch Validation: U87-luc cells are expanded under low-passage conditions (passage 3–8) in high-glucose DMEM supplemented with 10% FBS and 1% penicillin-streptomycin to preserve epithelial morphology and angiogenic phenotype. Viability is confirmed by trypan blue exclusion (>95% required), and luciferase expression is validated via in vitro bioluminescence assay to ensure uniform reporter signal intensity across the batch.
2. Animal Selection and Acclimation: Female athymic nude mice (Nu/Nu or BALB/c nude, 6–8 weeks old) are selected to accommodate human xenograft engraftment. A one-week acclimation period is observed under specific-pathogen-free housing, with daily health monitoring and body weight recording to establish individual baseline parameters.
3. Pre-Operative Analgesia and Anesthesia: Mice receive pre-operative analgesia comprising buprenorphine (0.1 mg/kg) and carprofen (5 mg/kg) subcutaneously. General anesthesia is induced and maintained with isoflurane (3% induction, 1.5–2% maintenance) delivered via nose cone, with continuous respiration and body temperature monitoring throughout the procedure.
4. Surgical Site Preparation: The scalp is shaved and depilatory cream is applied to remove fur, followed by sterilization with iodine solution. The mouse is secured in a stereotaxic frame with ear bars and a bite bar, and a single midline incision is made to expose the skull surface and identify the bregma and lambda landmarks.
5. Craniotomy and Dural Exposure: A small burr hole is drilled at the predetermined stereotactic coordinates (0.6 mm anterior to bregma, 1.8 mm lateral to the midline) using a high-speed microdrill under constant saline cooling. The dura mater is carefully pierced to expose the underlying parenchyma without causing cortical trauma or hemorrhage.
6. Tumor Cell Injection: A Hamilton syringe fitted with a fine micropipette is lowered through the burr hole to a depth of 3.0 mm below the skull surface, targeting the right corpus striatum. U87-luc cells (1 × 10⁵) in 5 µL sterile PBS are delivered at a constant rate of 0.5 µL per 30 seconds. A single-cell suspension is essential to prevent clumping and ensure uniform tumor seeding within the striatal parenchyma.
7. Needle Retraction and Wound Closure: The needle is left in place for an additional 3–5 minutes to prevent retrograde flow along the injection tract, then withdrawn slowly to minimize cell tracking. The burr hole is sealed with bone wax, the scalp incision is closed with surgical sutures, and the mouse is transferred to a heated recovery chamber.
8. Post-Operative Care and Monitoring: Mice receive carprofen-supplemented drinking water (33 µg/mL) for 72 hours post-surgery and are monitored twice daily for neurological deficits, body weight, and wound integrity. Animals are allowed to recover for a minimum of 3 days before initiation of any imaging or treatment protocol.
9. Bioluminescence Imaging and Tumor Monitoring: Starting at day 4–7 post-implantation, tumor establishment and growth are monitored via IVIS Spectrum or equivalent bioluminescence imaging system following intraperitoneal D-luciferin administration (150 mg/kg). Regions of interest are drawn over the cranial vault, and photon flux (photons/sec/cm²/sr) is quantified to generate longitudinal growth curves for each animal.
10. Endpoint Analysis and Neuropathology: At study termination, mice are humanely euthanized and brains are excised, weighed, and processed for formalin-fixed paraffin embedding. Coronal serial sections are stained with H&E for morphological assessment, and immunohistochemistry is performed for Ki67, CD31, EGFR, and human-specific cytokeratins to confirm tumor origin, proliferative index, vascular density, receptor expression, and species fidelity.

Fig 2. U87-luc Orthotopic Mouse Model construction workflow.

Case Study-U87-luc Orthotopic Mouse Model Development

In a representative preclinical engagement, the U87-luc orthotopic model was deployed to evaluate the efficacy of a novel iron oxide nanoparticle formulation combined with magnetic hyperthermia against CDKN2A-deleted glioblastoma. Following stereotactic implantation and confirmation of engraftment by bioluminescence imaging within the first week, cohorts were randomized to receive either the nanoparticle-hyperthermia regimen, nanoparticle alone, or vehicle control. Longitudinal BLI revealed distinct growth trajectories across treatment groups, with the combination cohort demonstrating attenuated photon flux accumulation relative to both monotherapy and control arms. Terminal neuropathological analysis showed reduced intracranial tumor burden, diminished microvascular proliferation, and lower Ki67 proliferation indices in treated animals, alongside preserved peritumoral brain architecture in responders. These preclinical findings informed the nanotherapeutic's mechanism-of-action hypothesis and supported advancement toward subsequent pharmacology and toxicology studies.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your U87-luc orthotopic glioblastoma program provides access to a benchmark human-xenograft-focused, quality-driven preclinical infrastructure optimized for intracranial tumor research and vascular-targeting therapy evaluation. Our core differentiators include:

• Unmatched experience with the U87 MG human glioblastoma model, the most historically validated glioma xenograft platform, with optimized stereotactic surgical protocols that achieve consistent striatal engraftment and predictable tumor kinetics in immunodeficient nude mice.
• Integrated bioluminescence and small-animal MRI imaging platforms enabling non-invasive, quantitative longitudinal tracking of intracranial tumor dynamics without introducing serial sacrifice artifacts into your dataset.
• Rigorous cell banking and authentication procedures, encompassing STR profiling, mycoplasma screening, luciferase expression validation, and low-passage maintenance to preserve epithelial morphology and angiogenic fidelity across batches.
• Adaptable study architectures supporting single-agent screening, combination temozolomide regimens, anti-angiogenic drug evaluation, nanoparticle-based therapeutic assessment, magnetic hyperthermia profiling, and blood-brain barrier penetration studies tailored to your therapeutic modality.
• Comprehensive neuropathological endpoint capabilities including digital histopathology, immunohistochemistry for CD31, Ki67, and EGFR, multiplex immunofluorescence, and human-specific marker confirmation to generate mechanistic insights alongside efficacy data.
• A dedicated scientific project management team providing transparent milestone reporting, timeline accountability, and direct consultation from protocol design through final data package delivery.

Contact Us

Whether your program targets glioblastoma with a novel anti-angiogenic agent, a nanoparticle-based delivery system, a magnetic hyperthermia approach, or a temozolomide combination strategy, Alfa Cytology is positioned to accelerate your preclinical development with our U87-luc orthotopic glioblastoma expertise. Contact us today to discuss your study design, review our imaging and surgical capabilities, and receive a customized proposal aligned with your scientific objectives and timeline. Our neuro-oncology team looks forward to collaborating with you to generate the robust, translationally relevant data your pipeline demands.

For research use only. Not intended for any clinical use.